The Miriam Hospital, 164 Summit Avenue, Providence, Rhode Island 02906, USA.
Oncologist. 2011;16(1):87-96. doi: 10.1634/theoncologist.2010-0213. Epub 2011 Jan 6.
Epstein-Barr virus-positive (EBV-positive) diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly described lymphoproliferative disorder recently included as a "provisional" entity in the most current WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The objective of this review is to provide a thorough and current summary of the existing knowledge of this subtype of DLBCL. We will review and discuss the incidence of EBV expression in DLBCL, the pathogenesis behind EBV-driven malignant transformation of B cells, the different EBV latency patterns associated with DLBCL, the distinct pathologic characteristics of EBV-positive DLBCL, the potential predictive and prognostic value of EBV tumoral status in patients with DLBCL, and potential strategies for the treatment of this rare entity, which is characterized by a suboptimal response to therapy and poor survival rate.
老年人 EBV 阳性（EBV 阳性）弥漫性大 B 细胞淋巴瘤（DLBCL）是一种新描述的淋巴增殖性疾病，最近被纳入当前世界卫生组织（WHO）造血和淋巴组织肿瘤分类中的“暂定”实体。本综述的目的是对这种 DLBCL 亚型的现有知识进行全面和当前的总结。我们将回顾和讨论 EBV 在 DLBCL 中的表达率、EBV 驱动 B 细胞恶性转化背后的发病机制、与 DLBCL 相关的不同 EBV 潜伏期模式、EBV 阳性 DLBCL 的独特病理特征、EBV 肿瘤状态对 DLBCL 患者的潜在预测和预后价值，以及这种罕见实体的潜在治疗策略，其特征是对治疗的反应不佳和生存率低。
